Top Page
China Health Group
(0673)
China Health Group (0673) vs. iShares MSCI Hong Kong ETF (EWH)
China Health Group Business Overview & Revenue Model
China Health Group Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 38.94M | 38.94M | 59.93M | 76.41M | 107.03M | 87.89M |
| Gross Profit | 9.23M | 9.23M | 13.64M | 27.19M | 28.69M | 25.99M |
| EBITDA | -63.71M | -63.71M | -37.42M | -33.04M | -4.38M | -1.47M |
| Net Income | -67.79M | -67.79M | -40.19M | -42.05M | -12.21M | -7.74M |
Balance Sheet | ||||||
| Total Assets | 147.35M | 147.35M | 192.32M | 221.19M | 225.96M | 217.82M |
| Cash, Cash Equivalents and Short-Term Investments | 1.05M | 1.05M | 4.01M | 11.48M | 8.54M | 4.59M |
| Total Debt | 6.50M | 6.50M | 5.66M | 6.04M | 18.47M | 5.36M |
| Total Liabilities | 147.25M | 147.25M | 132.56M | 127.23M | 140.82M | 117.83M |
| Stockholders Equity | -7.66M | -7.66M | 52.04M | 86.33M | 79.58M | 95.04M |
Cash Flow | ||||||
| Free Cash Flow | -8.35M | -8.35M | -7.03M | -9.59M | 31.00M | -10.90M |
| Operating Cash Flow | -6.76M | -6.76M | -6.40M | -8.22M | 31.80M | -9.06M |
| Investing Cash Flow | -1.58M | -1.58M | -301.00K | -5.40M | -35.29M | -1.84M |
| Financing Cash Flow | 8.79M | 8.79M | -1.24M | 27.66M | 12.96M | 2.63M |
China Health Group Technical Analysis
China Health Group Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | HK$64.54B | 8.78 | 8.74% | 3.75% | -2.68% | -21.45% | |
71 Outperform | HK$66.62B | 7.25 | 7.53% | 2.67% | 2.77% | 39.24% | |
62 Neutral | HK$3.78B | 20.09 | 5.07% | 3.81% | 0.33% | -44.28% | |
60 Neutral | HK$786.24M | 15.08 | 8.12% | 8.03% | ― | ― | |
52 Neutral | HK$1.06B | -7.66 | -465.55% | ― | -17.39% | -45.76% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
40 Underperform | HK$643.44M | -0.58 | -69.05% | ― | -43.86% | -217.25% |
China Health Group Corporate Events
China Health Group Limited reported its unaudited condensed consolidated interim financial results for the six months ending September 30, 2025. The company experienced a slight increase in revenue to HK$19,610,000 from HK$18,680,000 in the previous year. However, it faced a loss before tax of HK$10,889,000, which is an improvement from the previous year’s loss of HK$17,607,000. The total comprehensive loss for the period was HK$10,648,000, showing a reduction from the previous year’s loss of HK$18,130,000. Despite the losses, the financial results indicate a narrowing of losses, which could suggest potential stabilization or improvement in the company’s financial health.
The most recent analyst rating on (HK:0673) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on China Health Group stock, see the HK:0673 Stock Forecast page.
China Health Group Limited has announced a supplemental update to its annual report for the financial year ending March 31, 2025. The update highlights an impairment loss of approximately HK$11.7 million related to expected credit losses on loan and interest receivables. The company has taken legal action to recover a loan from Shuangluan Hospital, with ongoing litigation at the Chengde Court and discussions with the Shuangluan Government for possible repayment plans. The outcome of these actions could significantly impact the company’s financial recovery efforts and its stakeholders.
The most recent analyst rating on (HK:0673) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on China Health Group stock, see the HK:0673 Stock Forecast page.
China Health Group Limited announced measures to address liquidity pressures and a disclaimer of opinion on its financial statements for the year ending March 2026. The company successfully raised approximately HK$80.9 million through subscriptions and a rights issue, and plans to finalize bank borrowing negotiations by early 2026. The board remains vigilant in assessing operational and funding needs, advising shareholders to exercise caution when dealing with company securities.
The most recent analyst rating on (HK:0673) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on China Health Group stock, see the HK:0673 Stock Forecast page.
China Health Group Limited, a company incorporated in Bermuda and operating in Hong Kong, has announced a board meeting scheduled for November 28, 2025. The meeting will focus on reviewing and approving the unaudited interim results for the six months ending September 30, 2025, which could impact the company’s financial transparency and stakeholder confidence.
The most recent analyst rating on (HK:0673) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on China Health Group stock, see the HK:0673 Stock Forecast page.
China Health Group Limited, a company incorporated in Bermuda and operating in Hong Kong as CHG HS Limited, has announced the composition of its board of directors and the roles within its three board committees. The announcement details the executive, non-executive, and independent non-executive directors, as well as the members and chairpersons of the audit, nomination, and remuneration committees. This update provides stakeholders with clarity on the governance structure of the company, potentially impacting its strategic direction and operational oversight.
The most recent analyst rating on (HK:0673) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on China Health Group stock, see the HK:0673 Stock Forecast page.
China Health Group Limited has announced significant changes in its leadership structure, appointing Mr. Cao Xu as the new executive director and chairman of the board, effective October 31, 2025. Mr. Cao brings extensive experience in investments and the pharmaceutical industry, which is expected to enhance the company’s strategic direction and strengthen its market position. Additionally, Ms. Ying Rensi has been appointed as an executive director, further contributing to the company’s leadership team.
The most recent analyst rating on (HK:0673) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on China Health Group stock, see the HK:0673 Stock Forecast page.
China Health Group Limited has successfully completed the subscription of new shares and a rights issue, raising approximately HK$84.7 million in gross proceeds. The net proceeds of HK$80.9 million will be used to settle various financial obligations, including payables, loans, overdue salaries, and directors’ remuneration, as well as to provide working capital for daily operations.
The most recent analyst rating on (HK:0673) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on China Health Group stock, see the HK:0673 Stock Forecast page.
China Health Group Limited announced the results of its Rights Issue, which offered three Rights Shares for every ten shares held. The Rights Issue was undersubscribed by 18.9%, but all unsubscribed shares were successfully placed with independent placees, making the issue fully subscribed. The underwriting agreement conditions were fulfilled, and the Rights Issue became unconditional, ensuring no untaken rights shares remained.
The most recent analyst rating on (HK:0673) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on China Health Group stock, see the HK:0673 Stock Forecast page.